E-mail this page Printer Friendly Version RSS E-mail Alerts View contacts Download Financial Tear Sheet 

2013 Press Releases

This section of the website contains information that should be considered accurate as of the date presented. You acknowledge that this information may change over time and you should not assume that the information is accurate at a later date. Quest Diagnostics is not obligated to update the information contained in this section of the website.

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007
DateTitle 
12/12/13Quest Diagnostics Updates Revenue and Adjusted Diluted EPS Guidance for Full-Year 2013
MADISON, N.J., Dec. 12, 2013 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today updated its estimates for full-year 2013 revenues and adjusted diluted earnings per share, on a continuing operations basis and before special items.  The company previously updated its full-year 2013 guidance on October 17, 2013.   For the full-year 2013, the company expects: Revenues to be approximately 3.5% below the prior year, which is u... 
Printer Friendly Version
12/09/13BRCAvantage™ from Quest Diagnostics to Make Medical Congress Debut at the 2013 San Antonio Breast Cancer Symposium
Quest and Alamo Breast Cancer Foundation also Co-Hosting Panel on "Cancer and BRCA Testing in the News, the Arts and Popular Culture," Joined by Director of Upcoming Film "Decoding Annie Parker" MADISON, N.J., Dec. 9, 2013 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, announced that BRCAvantage™, a service-rich oncology offering designed to increase access to BRCA testing for at-risk patients and maximize the value of diagnos... 
Printer Friendly Version
12/06/13Quest Diagnostics Declares Quarterly Cash Dividend
MADISON, N.J., Dec. 6, 2013 /PRNewswire/-- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.30 per share, payable on January 22, 2014 to shareholders of record of Quest Diagnostics common stock on January 7, 2014. (Logo: http://photos.prnewswire.com/prnh/20130717/NY48934LOGO ) About Quest Diagnostics Quest Diagnostics is the world's leading provider of diagn... 
Printer Friendly Version
11/26/13Quest Diagnostics To Speak At The Piper Jaffray 25th Annual Healthcare Conference
MADISON, N.J., Nov. 26, 2013 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the Piper Jaffray 25th Annual Healthcare Conference in New York City.  Steve Rusckowski, the company's President and CEO, will discuss the company's vision, goals and five point strategy.  The presentation is scheduled for Tuesday, December 3, 2013 at 9:30 a.m. Eastern Time. (Logo:  http://photos.pr... 
Printer Friendly Version
11/18/13Drug Use Among American Workers Declined 74% Over Past 25 Years, Finds Unprecedented Analysis of More Than 125 Million Workplace Urine Drug Tests
Landmark Drug Testing Index™ analysis from Quest Diagnostics coincides with passage of the Drug-Free Workplace Act 25 years ago today MADISON, N.J., Nov. 18, 2013 /PRNewswire/ -- Drug use among American workers declined dramatically over the past 25 years, although the rate of positive test results for certain drugs, including amphetamine and opiates, continues to climb, according to a landmark analysis of workplace drug test results released today by Quest Diagnostics (NYSE: DGX), the worl... 
Printer Friendly Version
11/08/13Quest Diagnostics to Speak at the Credit Suisse 2013 Annual Healthcare Conference
MADISON, N.J., Nov. 8, 2013 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the Credit Suisse 2013 Annual Healthcare Conference in Arizona.  Steve Rusckowski, the company's President and CEO, will discuss the company's vision, goals and five point strategy.  The presentation is scheduled for Tuesday, November 12, 2013 at 1:00 p.m. Eastern Time. (Logo:  http://photos.prnewswi... 
Printer Friendly Version
10/17/13Quest Diagnostics Reports Third Quarter 2013 Financial Results; Updates Guidance for Full-Year 2013
MADISON, N.J., Oct. 17, 2013 /PRNewswire/ -- Adjusted diluted EPS from continuing operations of $1.02, vs. $1.15 in 2012 Reported diluted EPS from continuing operations of $2.66, vs. $0.98 in 2012 Revenues from continuing operations of $1.79 billion, 1.9% below prior year Full year 2013 revenues now expected to be approximately 3.5% below prior year Full year 2013 adjusted diluted EPS from continuing operations expected to be $3.85 to $3.95 Quest Diagnostics Incorporated (NYSE:... 
Printer Friendly Version
10/15/13National Survey Reveals Low Public Awareness and Understanding of BRCA Testing for Risk of Inherited Breast and Ovarian Cancers Among American Women
Seventy-two Percent (72 percent) of Adult Women in the U.S. Have Never Heard of BRCA Testing, yet 58 Percent Would Want to Know if They Carried High-Risk Gene Mutations MADISON, N.J., Oct. 15, 2013 /PRNewswire/ -- According to the results of a recent Quest Diagnostics (NYSE: DGX)  survey, seventy-two percent (72 percent) of American women age 18 and older have never heard of the BRCA test, a genetic test that can identify mutations in BRCA1 and BRCA2 genes associated with increased risk of ... 
Printer Friendly Version
10/15/13Quest Diagnostics Introduces BRCAvantage™, Broadly Expanding Patient Access to BRCA Genetic Testing for Inherited Breast and Ovarian Cancers
Also Releases Results from National Harris Survey Revealing Widespread Confusion about BRCA Testing MADISON, N.J., Oct. 15, 2013 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced the availability of BRCAvantage™, a suite of four new lab-developed genetic tests (LDT) that identify mutations in BRCA1 and BRCA2 genes, which are associated with increased risk of inherited breast and ovarian cancers. Serving an estimat... 
Printer Friendly Version
10/10/13Quest Diagnostics Provides Preview of Third Quarter 2013 Financial Performance
MADISON, N.J., Oct. 10, 2013 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today provided a preview of revenues and earnings per share for its third quarter ended September 30, 2013. The company has not yet finalized its financial results and intends to provide a full report on third quarter 2013 results, including updated 2013 guidance, and conduct a conference call with investors on October 17, 2013. (Logo: http://photos.prne... 
Printer Friendly Version
10/07/13Quest Diagnostics Acquires ConVerge Diagnostic Services
Transaction to expand patient access to innovative diagnostic information services and bolster Quest's growth strategy in New England MADISON, N.J. and PEABODY, Mass., Oct. 7, 2013 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, announced today that it has acquired ConVerge Diagnostic Services, LLC from Water Street Healthcare Partners, a strategic investor focused exclusively on the health care industry. ConVerge is a leading ... 
Printer Friendly Version
10/03/13Quest Diagnostics Again Listed on Dow Jones Sustainability World and North America Indices
MADISON, N.J., Oct. 3, 2013 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, has again been named to the Dow Jones Sustainability Indices (DJSI) for both World and North America. This marks Quest Diagnostics' tenth consecutive year on the World Index (since 2004) and its ninth consecutive year on the North America Index (since 2005). (Logo: http://photos.prnewswire.com/prnh/20130717/NY48934LOGO ) "Quest Diagnostics is committed... 
Printer Friendly Version
10/02/13Quest Diagnostics To Release Third Quarter 2013 Financial Results On October 17
MADISON, N.J., Oct. 2, 2013 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it will report third quarter 2013 results on Thursday, October 17, 2013 before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day. (Logo:  http://photos.prnewswire.com/prnh/20130717/NY48934LOGO) The conference call can also be accessed in listen-only mode by... 
Printer Friendly Version
10/01/13Quest Diagnostics Completes Sale of Enterix Business to Clinical Genomics of Australia
MADISON, N.J. and SYDNEY, Oct. 1, 2013 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that on September 30, 2013 it completed the sale of its Enterix colorectal cancer screening test business to Clinical Genomics Technologies Pty Ltd., an Australian life sciences company. Terms of the transaction were not disclosed. (Logo: http://photos.prnewswire.com/prnh/20130717/NY48934LOGO ) At its Investor Day presentatio... 
Printer Friendly Version
09/06/13Quest Diagnostics to Speak at the Morgan Stanley Global Healthcare Conference
MADISON, N.J., Sept. 6, 2013 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the Morgan Stanley Global Healthcare Conference in New York City. Steve Rusckowski, the company's President and CEO, will discuss the company's vision, goals and five point strategy.  The presentation is scheduled for Monday, September 9, 2013 at 10:00 a.m. Eastern Time. (Logo: http://photos.prnewsw... 
Printer Friendly Version
08/20/13Quest Diagnostics Increases Share Repurchase Authority by $1 Billion
Increase brings total current authorization to approximately $1.3 billion MADISON, N.J., Aug. 20, 2013 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors has increased the company's share repurchase authorization by $1 billion, bringing the total authorization to approximately $1.3 billion. (Logo:  http://photos.prnewswire.com/prnh/20130717/NY48934LOGO) "The increase i... 
Printer Friendly Version
08/20/13Quest Diagnostics Declares Quarterly Cash Dividend
MADISON, N.J., Aug. 20, 2013 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.30 per share, payable on October 16, 2013 to shareholders of record of Quest Diagnostics common stock on October 1, 2013. (Logo:  http://photos.prnewswire.com/prnh/20130717/NY48934LOGO) About Quest Diagnostics Quest Diagnostics is the world's leading provider of dia... 
Printer Friendly Version
08/14/13Quest Diagnostics Care360 is Top EHR, as Ranked by Doctors in 2013 Black Book Survey
Quest's electronic health record ranked number one for overall satisfaction across all physician categories; also ranked number one for mobile innovation and access MADISON, N.J., Aug. 14, 2013 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that its Care360 cloud-based electronic health record (EHR) has ranked number one in several categories in the Black Book 2013 Rankings of EHRs in the replacement market. Th... 
Printer Friendly Version
08/08/13Quest Diagnostics Introduces Comprehensive Opioid Therapy Genetic Test Based on CYP450 Biomarker License with Transgenomic
Believed to be first clinical test to identify variants of four enzymes that mediate drug metabolism, providing greater insights for guiding treatment for the more than 100 million Americans with chronic pain MADISON, N.J., Aug. 8, 2013 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced the availability of a new lab-developed genetic test to aid the delivery of personalized opioid pain-relieving treatment. It is be... 
Printer Friendly Version
07/26/13Harvard, MIT and Brown Students, MAP for Health and Quest Diagnostics Employees Again Rally Boston to Set "See No Evil, Hear No Evil, Speak No Evil" Guinness World Record, Drawing Attention to World Hepatitis Day
Volunteer Team Urges City Residents and Visitors to Come Out, Be Counted, and Paint at Hepatitis Awareness Event, Chinatown Park, 10:00 a.m. on July 28th. BOSTON, July 26, 2013 /PRNewswire/ -- Students at Harvard, Massachusetts Institute of Technology and Brown University, Massachusetts Asian & Pacific Islanders (MAP) for Health and local employee volunteers of Quest Diagnostics will join elected officials, community and healthcare leaders and Boston residents to once again rally the ci... 
Printer Friendly Version
07/25/13Quest Diagnostics and New York Giants Team Up in a Partnership to Enhance Athletes' Health and Performance
Giants Training Facility and Headquarters Renamed Quest Diagnostics Training Center EAST RUTHERFORD, N.J., July 25, 2013 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX) and the New York Giants are teaming up to find new ways to use laboratory diagnostic information services to improve the health and performance of athletes of all ages and abilities through a new collaboration. (Logo:  http://photos.prnewswire.com/prnh/20130717/NY48934LOGO ) The partnership was announced today at the Gi... 
Printer Friendly Version
07/18/13Quest Diagnostics Reports Second Quarter 2013 Financial Results
MADISON, N.J., July 18, 2013 /PRNewswire/ -- Adjusted diluted EPS from continuing operations of $1.06, vs. $1.15 in 2012 Reported diluted EPS from continuing operations of $0.99, vs. $1.09 in 2012 Revenues from continuing operations of $1.8 billion, 3.3% below prior year Full year 2013 revenues now expected to be 1% to 2% below prior year Full year 2013 EPS range narrowed to  $4.35 to $4.50 Sales of HemoCue and ibrutinib royalty rights for approximately $800 million provide fl... 
Printer Friendly Version
07/18/13Quest Diagnostics Sells Ibrutinib Royalty Rights To Royalty Pharma For $485 Million In Cash
Retains royalty rights to odanacatib and other Celera drug assets MADISON, N.J. and NEW YORK, July 18, 2013 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today that it has completed the sale of its rights to royalties from commercialization of the drug candidate ibrutinib to Royalty Pharma, the industry leader in acquiring royalty interests in marketed and late stage biopharmaceutical products, for $485... 
Printer Friendly Version
07/17/13Quest Diagnostics Names Mark J. Guinan as New CFO
MADISON, N.J., July 17, 2013 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX) today announced that Mark J. Guinan will join the company on July 29 as its next Senior Vice President and Chief Financial Officer.    Since 2010, Mr. Guinan has served as Chief Financial Officer for Hill-Rom Holdings Inc. (NYSE: HRC), a manufacturer and provider of medical technologies and related services for the health care industry. Previously, he had served in a number of finance and operations roles ... 
Printer Friendly Version
07/10/13Quest Diagnostics Partners with CDC to Improve Hepatitis C Public Health Research to Promote Early Detection and Medical Intervention
Collaboration aims to improve health outcomes for the estimated 3.2 million Americans infected with hepatitis C MADISON, N.J., July 10, 2013 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced a collaboration with the U.S. Centers for Disease Control and Prevention (CDC) to improve public health analysis of hepatitis C screening, diagnosis and treatment, based on analysis of the company's national hepatitis C virus ... 
Printer Friendly Version
07/02/13Quest Diagnostics To Release Second Quarter 2013 Financial Results On July 18
MADISON, N.J., July 2, 2013 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it will report second quarter 2013 results on Thursday, July 18, 2013 before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day. The conference call can also be accessed in listen-only mode by dialing 415-228-4961, passcode 3214469. The company suggests partici... 
Printer Friendly Version
06/26/13Quest Diagnostics Care360 EHR and Other Services Offered Through AT&T Healthcare Community Online
Goal to facilitate greater provider access to secure health data, promoting greater care coordination and improved cost efficiencies MADISON, N.J., June 26, 2013 /PRNewswire/ -- Quest Diagnostics (NYSE:DGX), the world's leading provider of diagnostic information services, today announced an agreement with AT&T* to provide the Quest Diagnostics Care360® Solution Suite, including the Care360 electronic health record (EHR) and eprescribing and laboratory order/results services, through AT&... 
Printer Friendly Version
06/24/13Quest Diagnostics Completes Acquisition of Lab-Related Clinical Outreach Operations of Dignity Health
Acquisition consistent with strategy to drive one to two percent in growth per year through strategically aligned fold-in acquisitions MADISON, N.J. and SAN FRANCISCO, June 24, 2013 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, announced today that it has completed the previously announced acquisition of lab-related clinical outreach service operations of Dignity Health, a hospital system based in California. Quest Diagno... 
Printer Friendly Version
06/06/13Quest Diagnostics CEO Steve Rusckowski Reaffirms Full-Year 2013 Guidance At The Jefferies 2013 Global Healthcare Conference
MADISON, N.J., June 6, 2013 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that Steve Rusckowski, President and CEO, presented at the Jefferies 2013 Global Healthcare Conference in New York City today. During the presentation, Mr. Rusckowski reaffirmed the company's guidance for its results from continuing operations, before special items, for the full-year 2013:   Revenues are expected to approximate th... 
Printer Friendly Version
06/06/13Quest Diagnostics and Hologic Form Strategic Alliance to Improve Women's Health
Collaboration features national availability of the APTIMA HPV mRNA-based cervical cancer screening test as well as a focus on developing and expanding access to diagnostic solutions for women's health MADISON, N.J. and BEDFORD, Mass., June 6, 2013 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading diagnostic information services company, and Hologic, Inc. (Hologic) (NASDAQ: HOLX), a leading developer, manufacturer and supplier of premium diagnostics products, medical imagin... 
Printer Friendly Version
06/05/13Quest Diagnostics To Speak At The Jefferies 2013 Global Healthcare Conference
MADISON, N.J., June 5, 2013 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that Steve Rusckowski, President and CEO, is scheduled to speak at the Jefferies 2013 Global Healthcare Conference in New York City on Thursday, June 6, 2013 at 1:00 p.m. Eastern Time. During the conference, Mr. Rusckowski will reaffirm the company's full-year 2013 guidance.  Revenues are expected to approximate the prior-year level... 
Printer Friendly Version
05/21/13Quest Diagnostics Declares Quarterly Cash Dividend
MADISON, N.J., May 21, 2013 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.30 per share, payable on July 17, 2013, to shareholders of record of Quest Diagnostics common stock on July 2, 2013. About Quest Diagnostics Quest Diagnostics is the world's leading provider of diagnostic information services that patients and doctors need to make bette... 
Printer Friendly Version
05/16/13Quest Diagnostics Acquires Concentra's Laboratory Business, Enters into Services Agreement
Patients, physicians and employers to benefit from greater access to broader menu of innovative diagnostic information services MADISON, N.J., May 16, 2013 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, announced today that it has acquired the toxicology and clinical laboratory business of medical center operator Concentra, a subsidiary of Humana Inc. (NYSE: HUM).  In addition, Quest Diagnostics has entered into a long-term ag... 
Printer Friendly Version
05/13/13Decades of Improving Cholesterol Levels Abruptly Ended in 2008, PLOS ONE Study Finds
Largest study of LDL blood levels, based on tests of nearly 105 million Americans, suggests improvements in cardiovascular health may have stalled in recent years MADISON, N.J., May 13, 2013 /PRNewswire/ -- Decades of declines in LDL cholesterol blood levels, a key marker of death risk from heart disease, abruptly ended in 2008, and may have stalled since, according to a multi-year, national study published in PLOS ONE. The study, by researchers at Quest Diagnostics (NYSE: DGX), examine... 
Printer Friendly Version
05/07/13Quest Diagnostics to Speak at the Bank of America Merrill Lynch 2013 Health Care Conference
MADISON, N.J., May 7, 2013 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the Bank of America Merrill Lynch 2013 Health Care Conference in Las Vegas. The presentation is scheduled for Wednesday, May 15, 2013 at 11:40 a.m. Eastern Time. The presentation will be webcast live during the conference and will be available to registered investors on the following site:  http://www... 
Printer Friendly Version
04/17/13Quest Diagnostics Reports First Quarter 2013 Financial Results
MADISON, N.J., April 17, 2013 /PRNewswire/ -- Adjusted diluted EPS from continuing operations of $0.89, vs. $1.05 in 2012 Reported diluted EPS from continuing operations of $0.72, vs. $0.97 in 2012 Revenues from continuing operations of $1.8 billion, 6.4% below prior year Full year 2013 adjusted EPS and cash flow guidance unchanged Full year 2013 revenues now expected to approximate the prior year level Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider o... 
Printer Friendly Version
04/17/13Quest Diagnostics to Acquire Lab-Related Clinical Outreach Operations of Dignity Health in California and Nevada
Transaction expected to deliver innovative and high-quality diagnostic information services at lower costs to patients MADISON, N.J. and SAN FRANCISCO, April 17, 2013 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, announced today that it has entered into a definitive agreement to acquire lab-related clinical outreach service operations of Dignity Health, a hospital system based in California. Under the agreement, Quest Dia... 
Printer Friendly Version
04/16/13Quest Diagnostics Names Jim Davis, Senior Vice President, Diagnostic Solutions
MADISON, N.J., April 16, 2013 /PRNewswire/ -- Quest Diagnostics (NYSE:DGX), the world's leading provider of diagnostic information services, announced today that Jim Davis, a former vice president for three GE healthcare businesses, has joined Quest Diagnostics as Senior Vice President, Diagnostic Solutions. In this role, Mr. Davis will lead the company's Diagnostic Solutions business. In this role, he will oversee Diagnostic Products, Insurer Services, Clinical Trials and Healthcare Informat... 
Printer Friendly Version
04/09/13Quest Diagnostics Completes Sale of HemoCue Business to Radiometer Medical ApS
MADISON, N.J., April 9, 2013 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that it has completed the sale of its HemoCue diagnostic products business to Radiometer Medical ApS for a purchase price of approximately $300 million plus customary adjustments for cash balances. HemoCue develops, produces and markets hemoglobin, glucose and other point-of-care testing systems worldwide. In February 2013, Quest Diagnos... 
Printer Friendly Version
04/09/13Quest Diagnostics Launches Novel Rheumatoid Arthritis Tests
Based on 14-3-3eta protein biomarker for aiding early RA diagnosis through an exclusive license with Augurex Life Sciences MADISON, N.J., April 9, 2013 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced the availability of two new blood tests for aiding the early diagnosis of rheumatoid arthritis (RA), an autoimmune disorder that can cause debilitating joint damage. The lab-developed tests are based on the prop... 
Printer Friendly Version
04/08/13Recreational Marijuana Users More Likely To Misuse Prescription Drugs, According to National Study by Quest Diagnostics
Quest Diagnostics Health Trends™ analysis also finds marijuana is the most commonly abused drug in the United States, but medical marijuana users are not more likely to misuse other drugs MADISON, N.J., April 8, 2013 /PRNewswire/ -- Individuals who use marijuana recreationally are more likely to misuse other drugs, including pain-controlling, but potentially addictive narcotics, sedatives and other prescription medications, than individuals who do not use marijuana, according to a new natio... 
Printer Friendly Version
04/05/13Quest Diagnostics To Release First Quarter 2013 Financial Results On April 17
MADISON, N.J., April 5, 2013 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it will report first quarter 2013 results on Wednesday, April 17, 2013 before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day. The conference call can also be accessed in listen-only mode by dialing 415-228-4961, passcode 3214469. The company suggests parti... 
Printer Friendly Version
04/03/13Prescription Drug Misuse Remains at Alarming Levels, According to National Study by Quest Diagnostics
Quest Diagnostics Health Trends™ analysis of a quarter million test results finds three out of five Americans tested misused their prescription medications, including through potentially dangerous drug combinations MADISON, N.J., April 3, 2013 /PRNewswire/ -- Despite increased public attention on the epidemic of prescription medication abuse, about three in five Americans tested misused their prescription drugs in 2012, virtually the same as in 2011, according to a national study issued tod... 
Printer Friendly Version
04/02/13Quest Diagnostics Names Sukumar Nagendran, M.D., Vice President, Medical Affairs
MADISON, N.J., April 2, 2013 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, announced today that Sukumar Nagendran, M.D., has joined Quest Diagnostics as vice president, medical affairs, a new position. In this role, Dr. Nagendran will provide medical oversight for the company's diagnostic information services. He reports to Jon R. Cohen, M.D., senior vice president and chief medical officer, and will be based at the company's h... 
Printer Friendly Version
03/27/13Federal Guidelines Recommend New HIV Testing Method
U.S. Department of Health and Human Services issues medical guidelines recommending genotypic testing to aid HIV therapy selection MADISON, N.J., March 27, 2013 /PRNewswire/ -- A new test based on gene sequencing may be used to assess a patient's suitability for treatment with CCR5 antagonists, a class of HIV antiretroviral therapies, under new medical guidelines issued by the U.S. Department of Health and Human Services (DHHS). The new genotypic test performs comparably to the standard... 
Printer Friendly Version
03/18/13Quest Diagnostics Launches Dementia Diagnostic Panel, First in Industry for Treatable Forms of Cognitive Impairment Based on Medical Guidelines
Test to be unveiled at the American Academy of Neurology Annual Meeting in San Diego, March 16-23, 2013 MADISON, N.J. and WORCESTER, Mass., March 18, 2013 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced the availability of the first clinical test panel for aiding the diagnosis of suspected dementia due to treatable forms of cognitive impairment. The test panel is believed to be the first commercial service from ... 
Printer Friendly Version
03/14/13Quest Diagnostics Announces Chief Financial Officer Transition Plan
MADISON, N.J., March 14, 2013 /PRNewswire/ -- Quest Diagnostics (NYSE:DGX), the world's leading provider of diagnostic information services, today announced that Robert A. Hagemann, Senior Vice President and Chief Financial Officer, plans to leave the company at the end of May 2013.  The company is launching a search for a new CFO that will consider both internal and external candidates, and Mr. Hagemann will assist in identifying his successor.  Mr. Hagemann will continue in his capacity as... 
Printer Friendly Version
03/14/13Quest Diagnostics Supports New Chronic Kidney Disease Guideline Focused on Predicting and Managing Risk
Public Encouraged to Learn About Their Kidneys and Understand Their Risks on World Kidney Day, March 14, 2013 MADISON, N.J., March 14, 2013 /PRNewswire/ -- On World Kidney Day, Quest Diagnostics, the world's leading provider of diagnostic information services, today announced its support of the updated global version of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF-KDOQI) Chronic Kidney Disease (CKD) guideline recently released by Kidney Disease: Improving G... 
Printer Friendly Version
03/07/13Pre-Employment Drug Test Positives Increase More Than 5%, According to New Data from Quest Diagnostics Drug Testing Index™
Marijuana Remains Most Commonly Detected; Oral Fluid Finding More Positives MADISON, N.J., March 7, 2013 /PRNewswire/ -- Job candidates subject to pre-employment drug screening tested positive for illicit drugs at a greater rate in the first six months of 2012 than in all of 2011, according to Drug Testing Index™ (DTI) data released today by Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services. The positivity rate from pre-employment urine drug s... 
Printer Friendly Version
03/05/13Quest Diagnostics to Showcase Its Award-Winning Healthcare IT Connectivity Solutions at HIMSS13
IT solutions enable physicians, hospitals, patients, ACOs and payers to be smart, synchronized and connected NEW ORLEANS, March 5, 2013 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, is presenting its award-winning healthcare information technology (HIT) connectivity solutions at HIMSS13.  Quest Diagnostics offers the broadest access to diagnostic information services through its network of laboratories and through it... 
Printer Friendly Version
03/04/13Quest Diagnostics Ranks No. 1 in Industry Category on FORTUNE's World's Most Admired Companies List
MADISON, N.J., March 4, 2013 /PRNewswire/ -- Quest Diagnostics (NYSE:DGX), the world's leading provider of diagnostic information services, today announced that that it has been recognized in FORTUNE magazine's "World's Most Admired Companies" list as the No. 1 company in the Health Care industry category of "Pharmacy and Other Services."  "We are proud that Quest Diagnostics has rejoined FORTUNE's World's Most Admired Companies as the leader in our category," said Steve Rusckowski, Pres... 
Printer Friendly Version
02/28/13ChartMaxx® and Appian Announce Partnership to Bring Next Generation Business Process Management to the Healthcare Industry at HIMSS13
Upgrade in functionality solves critical IT priorities, enables better patient experience, improves efficiency and provides greater return on investment for hospitals MASON, Ohio, Feb. 28, 2013 /PRNewswire/ -- In line with its reputation for being on the forefront of tools that provide insights for better healthcare, Quest Diagnostics (NYSE:DGX), the world's leading provider of diagnostic information services, today announced a partnership between ChartMaxx®, its leading Document Management... 
Printer Friendly Version
02/26/13Quest Diagnostics Declares Quarterly Cash Dividend
MADISON, N.J., Feb. 26, 2013 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.30 per share, payable on April 16, 2013, to shareholders of record of Quest Diagnostics common stock on April 2, 2013. About Quest Diagnostics Quest Diagnostics is the world's leading provider of diagnostic information services that patients and doctors need to mak... 
Printer Friendly Version
02/25/13Quest Diagnostics to Sell HemoCue Business to Radiometer Medical ApS
MADISON, N.J., Feb. 25, 2013 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that it has signed a definitive agreement to sell its HemoCue diagnostic products business to Radiometer Medical ApS for a purchase price of approximately $300 million plus customary adjustments for cash balances. HemoCue develops, produces and markets hemoglobin, glucose and other point-of-care testing systems worldwide. "The HemoCu... 
Printer Friendly Version
02/20/13Quest Diagnostics to Provide Nationwide Access to Natera's New Non-Invasive Prenatal Test
MADISON, N.J. and SAN CARLOS, Calif., Feb. 20, 2013 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading diagnostic information services company, and Natera, a leading innovator in prenatal genetic testing, today announced that Quest Diagnostics will offer physicians access to Panorama™, a new non-invasive prenatal test developed by Natera. Panorama uses cell-free fetal DNA in circulating maternal blood to screen for chromosomal abnormalities associated with trisomy 21 (Dow... 
Printer Friendly Version
02/11/13Quest Diagnostics Names Tracy L. Cinco-Abela Vice President and Treasurer
MADISON, N.J., Feb. 11, 2013 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that Tracy L. Cinco-Abela has been named vice president and treasurer. Ms. Cinco-Abela has responsibility for all treasury activities, including capital planning, capital markets and funding, financial risk management and treasury operations. Most recently, she served as the company's assistant treasurer. She reports to Robert A. Hage... 
Printer Friendly Version
02/08/13Quest Diagnostics To Speak At The Leerink Swann Global Healthcare Conference 2013
MADISON, N.J., Feb. 8, 2013 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the Leerink Swann Global Healthcare Conference in New York City. The presentation is scheduled for Thursday, February 14, 2013 at 11:00 a.m. Eastern Time. The presentation will be webcast live during the conference and will be available to registered investors on the following site: http://leerin... 
Printer Friendly Version
01/23/13Quest Diagnostics Reports Fourth Quarter And Full Year 2012 Financial Results; Announces 2013 Guidance
-- Full year record cash from operations of $1.2 billion and expanded operating margins -- Fourth quarter adjusted diluted EPS from continuing operations of $1.01, vs. $1.20 in 2011 -- Fourth quarter reported diluted EPS from continuing operations of $0.87 vs. $1.16 in 2011 -- Fourth quarter revenues from continuing operations of $1.8 billion, 4% below prior year -- 2013 guidance before special items: Diluted EPS between $4.35 - $4.55; revenues to grow between 0% and 1% MADISON,... 
Printer Friendly Version
01/16/13Quest Diagnostics Plans to Sell HemoCue Diagnostic Products Business as Part of its Strategy to Refocus on Diagnostic Information Services
-- Fourth Quarter Charge to be Recorded in Discontinued Operations -- -- Company Finalizes Estimated Impact from Hurricane Sandy -- MADISON, N.J., Jan. 16, 2013 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that it plans to sell its HemoCue diagnostic products business, as part of the company's strategy to refocus on diagnostic information services. HemoCue develops, produces and markets point-... 
Printer Friendly Version
01/08/13Quest Diagnostics To Speak At The 31st Annual J.P. Morgan Healthcare Conference
MADISON, N.J., Jan. 8, 2013 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the 31st Annual J.P. Morgan Healthcare Conference in San Francisco.  The presentation is scheduled for Wednesday, January 9, 2013 at 2:30 p.m. Eastern Time. The presentation will be webcast live during the conference and will be available to registered investors on the following site:  http://jpm... 
Printer Friendly Version
01/07/13Quest Diagnostics To Release Fourth Quarter And Full Year 2012 Financial Results On January 23
MADISON, N.J., Jan. 7, 2013 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it will report fourth quarter and full year 2012 results and provide financial guidance for 2013 on Wednesday, January 23, 2013 before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day. The conference call can also be accessed i... 
Printer Friendly Version
01/02/13Quest Diagnostics Acquires UMass Memorial Medical Center's Clinical and Anatomic Pathology Outreach Laboratory Businesses
Finalizes Lease to Build 200,000 Square Foot "Lab of the Future" in Marlborough, Massachusetts MADISON, N.J. and WORCESTER, Mass., Jan. 2, 2013 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced it has completed its previously announced acquisition of the Worcester-based clinical outreach laboratory business of UMass Memorial Medical Center, a member of UMass Memorial Health Care, the largest health care system in ... 
Printer Friendly Version